论文部分内容阅读
目的探讨支气管哮喘患者血清基质金属蛋白酶9(MMP-9)和基质金属蛋白酶1组织抑制剂(TIMP-1)水平的变化及其临床意义。方法采用酶联免疫吸附试验检测125例支气管哮喘患者和60例健康对照组患者血清MMP-9和TIMP-1水平。结果支气管哮喘患者发作组和缓解组血清MMP-9和TIMP-1及其二者比值均明显高于对照组(P<0.05,P<0.01),且发作组较缓解型组明显增高。结论检测支气管哮喘患者血清MMP-9和TIMP-1水平对临床诊断和治疗具有一定的指导意义。
Objective To investigate the changes of serum matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with bronchial asthma and its clinical significance. Methods Serum levels of MMP-9 and TIMP-1 in 125 patients with bronchial asthma and 60 healthy controls were detected by enzyme linked immunosorbent assay (ELISA). Results The ratio of serum MMP-9 and TIMP-1 in the onset and remission groups of bronchial asthma patients was significantly higher than that in the control group (P <0.05, P <0.01), and significantly higher in the attack group than in the remission group. Conclusion The detection of serum MMP-9 and TIMP-1 levels in patients with bronchial asthma has some guiding significance in clinical diagnosis and treatment.